Clinical Trials in Seoul, South Korea
3,633 recruiting
Showing 1–20 of 1,723 trials
Recruiting
Phase 1Phase 2
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497
Recruiting
Phase 3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
HR+/HER2- Breast Cancer
BeOne Medicines1,056 enrolled13 locationsNCT07492641
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled428 locationsNCT05980949
Recruiting
Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
COVID-19 (SARS-CoV-2) infection
Pfizer2,330 enrolled246 locationsNCT06679140
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled255 locationsNCT06937229
Recruiting
Phase 3
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
COVID-19 Infection
Pfizer300 enrolled147 locationsNCT07013474
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-small Cell Lung Cancer
AstraZeneca675 enrolled283 locationsNCT06357533
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ovarian Cancer
AbbVie400 enrolled73 locationsNCT07059845
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled383 locationsNCT07116967
Recruiting
Phase 2
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Phase 2
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer
AbbVie180 enrolled52 locationsNCT07155174
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled183 locationsNCT06646276
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 1Phase 2
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Metastatic Prostate Cancer
AstraZeneca42 enrolled8 locationsNCT07529717